Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 AM PST (2:15 PM EST). Live audio will be available via the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible for two weeks following the presentation.
This presentation offers investors and analysts direct access to management commentary and company updates on Pacira’s non-opioid pain therapy commercial and development priorities.
Positive
- None.
Negative
- None.
News Market Reaction – PCRX
In the Jan 7 session, PCRX gained 2.73%, reflecting a moderate positive market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Board nomination | Neutral | +0.0% | Investor group announced intent to nominate three director candidates. |
| Dec 18 | Research collaboration | Positive | -2.5% | Joined PROBE Consortium to advance osteoarthritis research using large OA datasets. |
| Dec 03 | Inducement grants | Neutral | +0.5% | Granted 2,200 RSUs to new hires under inducement plan with time-based vesting. |
| Dec 02 | Clinical study data | Positive | +1.6% | 12‑month pilot showed better pain and function outcomes for iovera° vs RFA. |
| Nov 26 | Patent litigation | Neutral | -1.0% | Filed EXPAREL patent infringement lawsuits against two counterparties. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly aligned with modest price reactions, with one notable divergence on a positive consortium collaboration update.
Over the last several months, Pacira BioSciences issued diverse updates, including a director nomination effort on Dec. 30, 2025, joining the PROBE osteoarthritis consortium on Dec. 18, 2025, and inducement RSU grants on Dec. 1, 2025. A 12‑month iovera° pilot study readout on Dec. 2, 2025 showed significant pain and functional benefits, while EXPAREL patent litigation was disclosed on Nov. 26, 2025. Today’s conference presentation notice fits into a pattern of ongoing scientific, strategic, and corporate communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com